Management of hereditary angioedema in 2012: Scientific and pharmacoeconomic perspectives

Annals of Allergy, Asthma and Immunology

Volumn 110, Issue 2, 2013, Pages 70-74

  Tilles, Stephen A ^a   Borish, Larry ^b   Cohen, Joshua P ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BERINET; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; ECULIZUMAB; ESTROGEN; GALSULFASE; ICATIBANT; IDURONATE 2 SULFATASE; IMIGLUCERASE; INFUSION FLUID; KALLIKREIN; KALLIKREIN INHIBITOR; ORAL CONTRACEPTIVE AGENT; PLACEBO; THROMBIN; UNCLASSIFIED DRUG;

ANALGESIA; ANGIONEUROTIC EDEMA; ANXIETY; ARTICLE; CELL MEMBRANE PERMEABILITY; CHOLESTASIS; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; ENDOTHELIUM CELL; FABRY DISEASE; GAUCHER DISEASE; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC CYSTITIS; HORMONE ACTION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; LIVER ADENOMA; LIVER FUNCTION TEST; MENSTRUAL CYCLE; METRORRHAGIA; MORQUIO SYNDROME; MYALGIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PHARMACOECONOMICS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SCIENTIFIC LITERATURE; SEX RATIO; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ACUTE DISEASE; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INACTIVATOR PROTEINS; DRUG COSTS; DRUG INDUSTRY; HUMANS; RARE DISEASES; TIME FACTORS;

EID: 84873177564     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2012.11.014     Document Type: Article

References (43)

1. B.L. Zuraw Clinical practice: hereditary angioedema N Engl J Med 359 2008 1027 1036
2. K. Bork, K. Siedlecki, S. Bosch, R.E. Schopf, and W. Kreuz Asphyxiation by laryngeal edema in patients with hereditary angioedema Mayo Clin Proc 75 2000 349 354
3. W.R. Lumry, A.J. Castaldo, and M.K. Vernon The humanistic burden of hereditary angioedema: impact on health related quality of life, productivity, and depression Allergy Asthma Proc 31 2010 407 414
4. V.H. Donaldson, and R.R. Evans A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C' 1-esterase Am J Med 35 1963 37 44
5. J. Alsenz, J.D. Lambris, and K. Bork Acquired C1 inhibitor (C1-INH) deficiency type II: replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies J Clin Invest 83 1989 1794 1799
6. K. Bork Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor Allergy Asthma Clin Immunol 6 2010 15
7. M.M. Frank The "neurotic" edema: the parent disease and its offspring Am J Med 113 2002 249 251
8. I.M. Nilsson, L. Andersson, and S.E. Bjorkman Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 year's clinical experience Acta Med Scand Suppl 448 1966 1 46
9. B. Lundh, A.B. Laurell, H. Wetterqvist, T. White, and G. Granerus A case of hereditary angioneuroticoedema, successfully treated with epsilon-aminocaproic acid: studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism Clin Exp Immunol 7 1968 733 745
10. R.H. Champion, and P.J. Lachmann Hereditary angio-oedema treated with E-aminocaproic acid Br J Dermatol 10 1969 763 765
11. M. Frank, J.A. Gelfand, D.W. Alling, and R.J. Sherins Epsilon aminocaproic acid for hereditary angioedema N Engl J Med 21 1977 1235 1236
12. A.L. Sheffer, K.F. Austen, and F.S. Rosen Tranexamic acid therapy in hereditary angioneurotic edema N Engl J Med 9 1972 452 454
13. G. Blohme Treatment of hereditary angioneuroticoedema with tranexamic acid: a random double-blind cross-over study Acta Med Scand 4 1972 293 298
14. P.J. Davis, F.B. Davis, and P. Charache Long-term therapy of hereditary angioedema (HAE): preventive management with fluoxymesterone and oxymetholone in severely affected males and females Johns Hopkins Med J 6 1974 391 398
15. W.F. Rosse, G.L. Logue, H.R. Silberman, and M.M. Frank The effect of synthetic androgens in hereditary angioneurotic edema: alteration of C1 inhibitor and C4 levels Trans Assoc Am Physicians 89 1976 122 132
16. A.L. Sheffer, D.T. Fearon, and K.F. Austen Clinical and biochemical effects of stanozolol therapy for hereditary angioedema J Allergy Clin Immunol 3 1981 181 187
17. M.M. Frank, J.A. Gelfand, and J.P. Atkinson Hereditary angioedema: the clinical syndrome and its management Ann Intern Med 5 1976 580 593
18. Attenuated androgens J.A. Gelfand, R.J. Sherins, D.W. Alling, and M.M. Frank Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities N Engl J Med 26 1976 1444 1448
19. S.W. Hosea, M.L. Santaella, E.J. Brown, M. Berger, K. Katusha, and M.M. Frank Long term therapy of hereditary angioedema with danazol Ann Intern Med 93 1980 809
20. T. Bowen, M. Cicardi, and H. Farkas 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema Allergy Asthma Clin Immunol 6 2010 24
21. J.E. Gadek, S.W. Hosea, and J.A. Gelfand Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor N Engl J Med 302 1980 542 546
22. S. Tilles, and L. Borish A new generation of hereditary angioedema treatments: remarkable advances clash with disturbing economic reality Ann Allergy Asthma Immunol 106 2011 264 266
23. CSL Behring initiates study of subcutaneous administration of C1-esterase inhibitor in patients with hereditary angioedema: phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor [press release] May 2012 CSL Behring King of Prussia, PA
24. B.L. Zuraw, P.J. Busse, and M. White Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema N Engl J Med 363 2010 513 522
25. B.L. Zuraw, and I. Kalfus Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema Am J Med 125 2012 938.e1 938.e7
26. J.L. Martello, M.R. Woytowish, and H. Chambers Ecallantide for treatment of acute attacks of hereditary angioedema Am J Health Syst Pharm 69 2012 651 657
27. T.J. Craig, R.J. Levy, and R.L. Wasserman Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks J Allergy Clin Immunol 124 2009 801 808
28. M. Cicardi, R.J. Levy, and D.L. McNeil Ecallantide for the treatment of acute attacks in hereditary angioedema N Engl J Med 363 2010 523 531
29. R.J. Levy, W.R. Lumry, and D.L. McNeil EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema Ann Allergy Asthma Immunol 104 2010 523 529
30. M. Cicardi, A. Banerji, and F. Bracho Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema N Engl J Med 363 2010 532 541
31. W.R. Lumry, H. Henry Li, and R.J. Levy Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3trial Ann Allergy Asthma Immunol 107 2011 529 537
32. B. Zuraw, M. Cicardi, and R.J. Levy Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema J Allergy Clin Immunol 126 2010 821 827.e14
33. Orphan Drug Regulations (57 FR 62076), December 29, 1992 and 21 CFR Part 316 et seq.
34. C.R. Blankart, T. Stargardt, and J. Schreyogg Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukemia Pharmacoeconomics 29 2011 63 82
35. K.I. Kaitin U.S. Orphan Product Designations More Than Doubled From 2000-02 to 2006-08: Tufts Center for the Study of Drug Development Impact Report Jan/Feb 2010 Tufts Center for the Study of Drug Development Boston, MA 12(1)
36. M. McCaughan Big pharma and orphan drugs: the case for thinking small RPM Rep 4 2009 10 11
37. E. Seoane-Vazquez, R. Rodriguez-Monguio, S.L. Szeinbach, and J. Visaria Incentives for orphan drug research and development in the United States Orphanet J Rare Dis 3 2008 33
38. M.M. Frank, and H. Jiang New therapies for hereditary angioedema: disease outlook changes dramatically J Allergy Clin Immunol 121 2008 272 290
39. Z. Rosenberg-Yunger, A. Daar, H. Thorsteinsdottir, and D. Martin Priority setting for orphan drugs: an international comparison Health Policy 10 2011 25 34
40. E. Largent, and S. Pearson Which orphans will find a home: the rule of rescue in resource allocation for rare diseases Hastings Center Rep 42 2012 27 34
41. D. Klepser, J. Huether, L. Handke, and C. Williams Effect on drug utilization and expenditures of a cost-share change from co-payment to co-insurance J Managed Care Pharmacy 13 2007 765 777
42. A. Wilson, and J. Cohen Patient access to new cancer drugs in the United States and Australia Value Health 14 2011 944 952
43. R. Hyde, and D. Dobrovolny Orphan drug pricing and payer management in the United States: are we approaching a tipping point? Am Health Drug Benefits 3 1 2010 www.AHDBonline.com